VANTIN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for VANTIN (VANTIN).
Cefpodoxime proxetil is a semisynthetic third-generation cephalosporin antibiotic. It inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
| Metabolism | Cefpodoxime proxetil is a prodrug that is de-esterified to the active metabolite cefpodoxime primarily by intestinal esterases. Cefpodoxime undergoes minimal hepatic metabolism; elimination is mainly renal via glomerular filtration and tubular secretion. |
| Excretion | Approximately 80-90% of cefpodoxime is excreted unchanged in the urine within 24 hours, mainly by glomerular filtration and tubular secretion. A small fraction is eliminated via bile and feces. |
| Half-life | The terminal elimination half-life in adults with normal renal function is about 2.2-2.8 hours. In children, it is approximately 1.5-2 hours. Prolonged half-life in renal impairment (up to 9-10 hours in severe impairment) requires dose adjustment. |
| Protein binding | About 21-29% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Volume of distribution is approximately 0.6-1.2 L/kg, indicating distribution into extracellular fluid and some tissues. It penetrates well into blister fluid, bronchial mucosa, and tonsils. |
| Bioavailability | Oral bioavailability of cefpodoxime proxetil is about 50% (range 40-60%) when taken with food. It is increased by food (high-fat meal enhances absorption). The prodrug is rapidly desterified to active cefpodoxime. |
| Onset of Action | Peak plasma concentrations occur about 2-3 hours after oral administration. Clinical response typically begins within 24-48 hours for most infections. |
| Duration of Action | Bactericidal activity persists for approximately 12 hours, supporting a twice-daily dosing regimen. Clinical cure is achieved with standard 5-14 day courses depending on infection type. |
100-200 mg orally twice daily for 10-14 days for community-acquired pneumonia; 100 mg orally twice daily for 5-7 days for acute exacerbations of chronic bronchitis; 100 mg orally twice daily for 10 days for uncomplicated skin and skin structure infections; 100 mg orally twice daily for 3-7 days for uncomplicated urinary tract infections; 200 mg orally twice daily for 10 days for complicated urinary tract infections.
| Dosage form | TABLET |
| Renal impairment | CrCl 30-49 mL/min: 100 mg every 24 hours; CrCl <30 mL/min: 100 mg every 48 hours; hemodialysis: 100 mg after each dialysis session (administered 3 times weekly). |
| Liver impairment | No dosage adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not studied in severe hepatic impairment (Child-Pugh C), use with caution. |
| Pediatric use | For acute otitis media, pharyngitis/tonsillitis, and impetigo: 10 mg/kg (max 400 mg) orally twice daily for 10 days; for uncomplicated urinary tract infections: 10 mg/kg (max 200 mg) orally twice daily for 3-7 days. |
| Geriatric use | No specific geriatric dose adjustment; base dosing on renal function. Monitor for adverse effects due to age-related renal impairment. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for VANTIN (VANTIN).
| Breastfeeding | Cefpodoxime proxetil is excreted in human milk in low concentrations. The milk-to-plasma ratio is not well established, but estimated to be low. Caution should be exercised when administered to a nursing woman. Consider the developmental and health benefits of breastfeeding along with the mother's clinical need for the drug and any potential adverse effects on the breastfed child from the drug or underlying maternal condition. |
| Teratogenic Risk | There are no adequate and well-controlled studies in pregnant women. Animal reproduction studies have not revealed evidence of harm to the fetus. Because animal studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. No teratogenic effects reported in animal studies; however, as with all antibiotics, use in first trimester should be cautious due to potential effects on fetal development. |
■ FDA Black Box Warning
None.
| Serious Effects |
["Hypersensitivity to cefpodoxime or other cephalosporins","Hypersensitivity to penicillins or other beta-lactams (potential cross-reactivity)"]
| Precautions | ["Hypersensitivity reactions including anaphylaxis","Clostridioides difficile-associated diarrhea","Superinfection with prolonged use","Reduced efficacy in patients with renal impairment (dosage adjustment required)","Potential for seizure activity if high doses are given to patients with renal impairment"] |
Loading safety data…
| Fetal Monitoring | Monitor for signs of hypersensitivity reactions, diarrhea (Clostridium difficile infection), and superinfection. No specific fetal monitoring required, but routine prenatal care should continue. In pregnant women, monitor renal function as dose adjustment may be needed in impaired renal function. |
| Fertility Effects | No studies on fertility have been conducted in humans. Animal studies have not shown impaired fertility at clinically relevant doses. No known adverse effects on male or female fertility. |